Martingale Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Martingale Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-27,526	Closed	-$87.3K	–	786
2023 Q3	$87.3K	Buy	27,526 +3,300	+14%	+$14.5K	﹤0.01%	770
2023 Q2	$120K	Sell	24,226 -5	-0%	-$27	﹤0.01%	785
2023 Q1	$120K	Hold	24,231	–	–	﹤0.01%	802
2022 Q4	$152K	Hold	24,231	–	–	﹤0.01%	807
2022 Q3	$262K	Sell	24,231 -800	-3%	-$10.9K	0.01%	737
2022 Q2	$286K	Sell	25,031 -15	-0.1%	-$133	0.01%	741
2022 Q1	$229K	Hold	25,046	–	–	﹤0.01%	775
2021 Q4	$374K	Buy	25,046 +2,925	+13%	+$51.6K	﹤0.01%	697
2021 Q3	$569K	Buy	22,121 +5,000	+29%	+$119K	0.01%	642
2021 Q2	$447K	Buy	+17,121	New	+$488K	0.01%	618

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Martingale Asset Management's ALLO Position: Q4 2023 in Review

Martingale Asset Management sold out of Allogene Therapeutics (ALLO) in Q4 2023, closing a stake of 27,526 shares — an estimated $87.3K sold.

Martingale Asset Management first reported a position in ALLO in Q2 2021 and held it in 10 quarters. The position peaked at $569K in Q3 2021. 170 funds tracked by Wall St. Rank hold ALLO as of Q4 2023.

Martingale Asset Management reported no remaining Allogene Therapeutics position as of Q4 2023 after selling out during the quarter.
Martingale Asset Management sold 27,526 Allogene Therapeutics shares in Q4 2023, an estimated $87.3K.
Martingale Asset Management first reported a position in Allogene Therapeutics in Q2 2021 and held it in 10 quarters.
Martingale Asset Management's Allogene Therapeutics position peaked at $569K in Q3 2021.
170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2023.

Based on Martingale Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.